Hofseth Biocare Asa Stock Cash Per Share
| HBC Stock | NOK 2.30 0.04 1.71% |
Hofseth Biocare ASA fundamentals help investors to digest information that contributes to Hofseth Biocare's financial success or failures. It also enables traders to predict the movement of Hofseth Stock. The fundamental analysis module provides a way to measure Hofseth Biocare's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hofseth Biocare stock.
Hofseth |
Hofseth Biocare ASA Company Cash Per Share Analysis
Hofseth Biocare's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Hofseth Biocare Cash Per Share | 0.12 X |
Most of Hofseth Biocare's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hofseth Biocare ASA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Hofseth Biocare ASA has a Cash Per Share of 0.12 times. This is 97.24% lower than that of the Healthcare sector and 97.23% lower than that of the Biotechnology industry. The cash per share for all Norway stocks is 97.6% higher than that of the company.
Hofseth Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hofseth Biocare's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hofseth Biocare could also be used in its relative valuation, which is a method of valuing Hofseth Biocare by comparing valuation metrics of similar companies.Hofseth Biocare is currently under evaluation in cash per share category among its peers.
Hofseth Fundamentals
| Return On Equity | -0.95 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (1.07) % | |||
| Current Valuation | 1.03 B | |||
| Shares Outstanding | 395.08 M | |||
| Shares Owned By Insiders | 52.50 % | |||
| Shares Owned By Institutions | 20.43 % | |||
| Price To Earning | (4.13) X | |||
| Price To Book | 5.19 X | |||
| Price To Sales | 8.29 X | |||
| Revenue | 87.62 M | |||
| Gross Profit | 28.51 M | |||
| EBITDA | (87.72 M) | |||
| Net Income | (126.46 M) | |||
| Cash And Equivalents | 36.52 M | |||
| Cash Per Share | 0.12 X | |||
| Total Debt | 123.31 M | |||
| Debt To Equity | 188.20 % | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | 0.39 X | |||
| Cash Flow From Operations | (61.78 M) | |||
| Earnings Per Share | (0.38) X | |||
| Beta | 0.54 | |||
| Market Capitalization | 1.1 B | |||
| Total Asset | 415.97 M | |||
| Retained Earnings | (105 M) | |||
| Working Capital | (22 M) | |||
| Current Asset | 52 M | |||
| Current Liabilities | 74 M | |||
| Z Score | 4.8 | |||
| Net Asset | 415.97 M |
About Hofseth Biocare Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hofseth Biocare ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hofseth Biocare using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hofseth Biocare ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Hofseth Stock
Hofseth Biocare financial ratios help investors to determine whether Hofseth Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hofseth with respect to the benefits of owning Hofseth Biocare security.